According to "Puhua Capital Guanghua Medical College Accurate Medicine Private Enjoyment", Aiji Taikang founder Hang Xingyi made a share, edited by the "Peptide Chain" editor.
"gate" type technology
First science, what is genetic capture? The human genome consists of 3 billion base pairs. The process of enriching any locus, gene fragment or gene length is called gene capture. It is a bit like a capture, so it is also called Gene Capture.
In fact, the products enriched in the process of gene capture can be docked with a variety of detection techniques. Due to its high-throughput characteristics, it is the most widely used for second-generation sequencing detection.
The second-generation sequencing industry chain is based on sequencer, sample extraction, database building, capture, sequencing, and data analysis. Most of the industry's businesses are distributed in this technology chain.
Aiji Taikang is the design and development of genetic testing products based on capture technology. What are the characteristics of gene capture technology?
First, gene capture technology can be used to derive a variety of products, such as tumors, genetic diseases, and reproduction in precision medicine .
Secondly, capture sequencing is the need for accurate detection. It can achieve high sensitivity and high accuracy based on depth, which is the application scenario that can not be met by genome-wide sequencing.
Again, gene capture has barriers in both technology and systems, and it cannot be easily broken at present.
Therefore, we believe that gene capture is a gateway technology in the entire industry chain. I think that gateway technology has two characteristics: first, technical barriers are relatively high; second, technology-derived products.
Gateway technology is not a universal technology and product, it has many possibilities for commercialization of application scenarios.
2015 is the first year of precision medicine . The National Institutes of Health (NIH) proposed three opportunities at that time: the rapid development of gene sequencing technology; the emergence of big data on the Internet; the continuous promotion of bioinformatics and cloud computing, making precision medicine The landing has a very strong feasibility.
Aiji Taikang also started operations in 2015, and our hybrid capture technology and multiplex PCR amplification technology were officially developed;
At the end of 2017, the first all-exon capture chip designed and developed by our Chinese was also completed by Aiji Taikang;
In 2018, we made another major breakthrough in methylation capture.
According to incomplete statistics, there are about $8 billion in market space for the second generation of sequencing in the world in 2018. From the perspective of market growth, the second-generation sequencing market has a compound growth rate of at least 25% per year.
From technical classification, there are whole genome sequencing, capture sequencing, transcriptome sequencing, methylation sequencing and so on.
According to the 2016 consultation statistics, capture and sequencing accounted for 46% of all NGS sequencing markets. By 2018, it is almost close to 60% of the market share, mainly benefiting from the outbreak of capture sequencing in precision medical applications in recent years.
Most of the sequencing tests used in precision medicine use three technologies: targeted sequencing, whole exome sequencing or whole genome sequencing.
Targeted sequencing and whole exome sequencing are our core products and services, accounting for more than 90% of precision medical sequencing applications.
As long as it is to do precise medical gene sequencing, the basic 90% probability of sequencing is to use targeted sequencing for detection.
Platform company
Most of the companies in the precision medical industry were established in the three years of 2014, 2015 and 2016. Now everyone is facing development problems.
How to develop? The most important thing from the initial stage to the development stage is the ability to realize the technology, that is, its own ability to hematopoietic. Of course, Ai Ji Taikang has never forgotten the initial intention of technology-driven.
Any technology or product has its life cycle. One technology may be 5-10 years, and one product may be 1-3 years. Therefore, it should be 3-5 years ahead of the strategic technology research and development, to make the layout for the next market cycle.
We believe that 2018-2023 is a period of rapid development and technological change for this wave of genetic industry companies, so we must seize the opportunity of 3-5 years to achieve cash flow growth, while at the same time doing the next wave of new technologies. Well prepared.
In the past three years, we feel that this industry is developing very fast. A specific product or a technology needs to be rapidly expanded and applied at a speed that exceeds any previous era, so as to avoid the ceiling coming too quickly.
Therefore, we have carried out a strategic upgrade in combination with the development reality, that is, a technology-driven production service platform company in the genetic testing industry.
This is a process based on the continuous extension of the gateway technology, the application of continuous upgrading and enterprise platformization.
In the past three years, we have done a lot of genetic testing panels, product sales rights, approval rights, pricing rights and dividend rights have been given to customers without reservation, we are equivalent to establishing efficient production and cost centers for customers, let They can do more with the business model.
Aiji Taikang will eventually evolve into a technology platform company. At present, we are guided by gene capture technology to cut the industry chain horizontally. As long as we are involved in the application related to gene capture, we will also have various forward-looking layouts. New technologies continue to expand with the same model.
Technical empowerment
Ai Ji Taikang's product service strategy is "one special multi-energy, technical empowerment". The so-called "one special" means that all applications focus on gene capture technology.
Platform companies don't mean many things. In fact, any application in our background will focus on hybrid capture and multiplex PCR, which is high-throughput but very standardized.
“Technology empowerment†is the core embodiment of application upgrade. Now, what areas does our technology enable?
First of all, the most important application area is precision medicine. Our company is born out of the development of precision medicine. Precision medicine involves most of the clinical departments of the hospital. The most widely used applications are the following four directions:
First, the tumor. From the earliest tissue concomitant diagnosis to liquid biopsy, to the tumor immune TMB assessment, we currently have major hospitals and clinical inspection companies;
Second, genetic diseases. A wide variety of genetic tests for a wide range of genetic diseases and rare diseases, from the initial single-path Panel to the full-scale application of the medical version to the present, we have gone through the whole process;
Third, reproduction. Genetic testing in the field of reproduction NIPT is currently the mainstream, NIPT is mainly to detect Down's syndrome, but how to carry out reproductive testing of other genetic diseases? CMA chips, capture sequencing and whole-genome sequencing are three types of technologies that are currently used frequently. The three technologies, especially for CNV detection, currently have their own advantages;
Fourth, stem cells and immunity. When screening stem cell ligands and donors, HLA genotyping is essential for organ transplantation.
Secondly, the rapid application of gene capture technology is great health. We distinguish between the detection of healthy people and medical genetic testing. The potential for application development in this field is huge.
2-Piece Ostomy pouch MDK-BO-02 500ML
A one-piece colostomy bags, drainable pouching system designed to be opened at the bottom when emptying. These colostomy bag machine are most suitable for colostomies or ileostomies. Ostomy bag colostomy barrier is a standard wear skin barrier that is gentle to the skin and allows for frequent pouch removal. To close the pouch, use the curved, beige clamp. Soft, beige disposable colostomy bag pouch panels on body side help provide comfort.
The features are soft and flex,standard wear, skin barrier, flat. The Chassis made in 100% hydrocolloid No tape border. Cut-to-fit skin barrier. Ultra-clear odor-barrier pouch film. Curved, beige pouch clamp. With comfortable ware pouch panel body side only. Not made with natural rubber latex.
Ostomy urostomy colostomy bag care products consist of sodium carboxymethylcellulose, adhesives made from medical hot melt adhesives, and separator paper or separators. Nursing equipment for ileum, colon, rectum or urethral stoma,The coloplast colostomy bag comes into contact with intact skin and intestinal lumen,Non-sterile supply. Colostomy bag reusable for stoma washing, care and collection of excreta and skin care around the stoma.
Use disposable colostomy bag, make sure the skin around the stoma is clean and dry before use. Remove the bags for colostomi from the package and separator or paper. Reshape the coloplast colostomy bag into the desired shape and size to fit the skin around the stoma. Apply the colostomy convatec bag to the skin around the stoma,adjust the shape of the paste again,Gently press so that it is firmly flat on the skin. Attach the stoma colostomy bag undercarriage to the stoma. The colostomy bag care can be peeled off the skin, don`t reuse. These one-piece-colostomy bag or two-piece-colostomy-bag are non-sterile product and is valid for three years under the condition of meeting the storage conditions.
1-Piece Ostomy Pouch,One Piece Ostomy Bags,One Piece Ostomy Pouch,1 Piece Ostomy Bag
Henan Maidingkang Medical Technology Co.,Ltd , https://www.mdkmedicales.com